{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:13:58Z","timestamp":1762838038841,"version":"build-2065373602"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>A nomogram predicting lung metastasis in patients with papillary thyroid cancer was developed and validated. Our study focused on patients under 55 years old, revealing the genetic factors linked to lung metastasis in this younger group. Young patients with the BRAF V600E mutation are less likely to develop lung metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop and validate a nomogram for predicting the risk of lung metastasis in patients under 55 years old with papillary thyroid cancer (PTC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 243 patients under 55 years old with PTC were retrospectively collected from January 2017 to June 2020 and randomly divided into a training group (n = 170) and a validation group (n = 73) in a 7:3 ratio. Genetic testing data and clinical information were compiled, and univariate and multivariate binary logistic regression analyses were performed. Based on the results, a nomogram predicting the risk of lung metastasis was constructed using the training cohort. The nomogram\u2019s performance was assessed using calibration curves, decision curve analysis (DCA), the concordance index (C-index), and the area under the receiver operating characteristic (ROC) curve (AUC) in both the training and validation groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>T stage, unilateral thyroid involvement, TERT mutation, and BRAF mutation were identified as independent prognostic factors and were used to construct the nomogram. The C-index of the model was 0.89 in the training group and 0.88 in the validation group. The AUC, DCA, and calibration curves demonstrated favorable predictive accuracy. Using a cut-off value of 0.229, the nomogram achieved a sensitivity of 0.829 and a specificity of 0.793.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A nomogram with strong predictive performance has been successfully developed and validated, which may assist clinicians in estimating the risk of lung metastasis in young patients with PTC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1689674","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:10:49Z","timestamp":1762837849000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A Nomogram for Predicting Lung Metastasis in Papillary Thyroid Cancer Patients Aged Less Than 55 Years"],"prefix":"10.3389","volume":"16","author":[{"given":"Huiyun","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuqin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0190","article-title":"Standard and emerging therapies for metastatic differentiated thyroid cancer","volume":"15","author":"O'Neill","year":"2010","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40463-020-00469-8","article-title":"Patient and tumor factors contributing to distant metastasis in well-differentiated thyroid cancer: a retrospective cohort study","volume":"49","author":"Khan","year":"2020","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.800639","article-title":"Nomogram individually predicts the risk for distant metastasis and prognosis value in female differentiated thyroid cancer patients: A SEER-based study","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14389","article-title":"Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis","volume":"111","author":"Lan","year":"2020","journal-title":"Cancer Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071625","article-title":"Site-specific metastasis and survival in papillary thyroid cancer: the importance of brain and multi-organ disease","volume":"13","author":"Toraih","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13489","article-title":"Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up","volume":"88","author":"Sohn","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04923-7","article-title":"Cut-off values for diagnosis of G6PD deficiency by flow cytometry in Thai population","volume":"101","author":"Thedsawad","year":"2022","journal-title":"Ann Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e34581","DOI":"10.1097\/MD.0000000000034581","article-title":"Development and validation of a nomogram for risk of pulmonary metastasis in non-papillary thyroid carcinoma: A SEER-based study","volume":"102","author":"Li","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5555","article-title":"Analysis of factors associated with the prognosis of papillary thyroid cancer and the construction of a survival model","volume":"12","author":"Guo","year":"2023","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"L7","DOI":"10.1530\/ERC-17-0453","article-title":"8th edition of the AJCC\/TNM staging system of thyroid cancer: what to expect (ITCO2)","volume":"25","author":"Lamartina","year":"2018","journal-title":"Endocr Relat Can"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/EC-13-0056","article-title":"The age factor in survival of a population cohort of well-differentiated thyroid cancer","volume":"2","author":"Mazurat","year":"2013","journal-title":"Endocr Con"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2020.11.018","article-title":"How does the AJCC\/TNM staging system eighth edition perform in thyroid cancer at A major middle eastern medical center","volume":"27","author":"Alzahrani","year":"2021","journal-title":"Endocr Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa545","article-title":"Distant metastasis in pediatric and adolescent differentiated thyroid cancer: clinical outcomes and risk factor analyses","volume":"105","author":"Sugino","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1228049","article-title":"Predictive risk factors for distant metastasis in pediatric differentiated thyroid cancer from Saudi Arabia","volume":"14","author":"Parvathareddy","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2018.33.2.287","article-title":"Prognosis of differentiated thyroid carcinoma with initial distant metastasis: A multicenter study in korea","volume":"33","author":"Kim","year":"2018","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4158\/EP171924","article-title":"Long-term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases","volume":"23","author":"Hirsch","year":"2017","journal-title":"Endocr Pract"},{"key":"B19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/thy.2016.0347","article-title":"Initial size of metastatic lesions is best prognostic factor in patients with metastatic differentiated thyroid carcinoma confined to the lung","volume":"27","author":"Kim","year":"2017","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/thy.2020.0002","article-title":"Lung metastasis in children with differentiated thyroid cancer: factors associated with diagnosis and outcomes of therapy","volume":"31","author":"Chesover","year":"2021","journal-title":"Thyroid"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2023-0425","article-title":"Predictive factors for lung metastasis in pediatric differentiated thyroid cancer: a clinical prediction study","volume":"37","author":"Kuang","year":"2024","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2024.05.002","article-title":"Radioactive iodine therapy in differentiated thyroid cancer: an update on dose recommendations and risk of secondary primary Malignancies","volume":"54","author":"Nguyen","year":"2024","journal-title":"Semin Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ23-0413","article-title":"Risk factors for mediastinal lymph node metastasis and lung metastasis in papillary thyroid carcinoma patients: who benefits from preoperative computed tomography","volume":"71","author":"Omi","year":"2024","journal-title":"Endocr J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr Relat Can"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030749","article-title":"The solo play of TERT promoter mutations","volume":"9","author":"Hafezi","year":"2020","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/11795549221140781","article-title":"TERT mutations in non-small cell lung cancer: clinicopathologic features and prognostic implications","volume":"17","author":"Yang","year":"2023","journal-title":"Clin Med Insights Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2785","article-title":"TERT, BRAF, and NRAS in primary thyroid cancer and metastatic disease","volume":"102","author":"Melo","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/srep36990","article-title":"TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: A meta-analysis","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.808298","article-title":"TERT promoter mutations are an independent predictor of distant metastasis in middle eastern papillary thyroid microcarcinoma","volume":"13","author":"Parvathareddy","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0338","article-title":"Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET\/PTC rearrangements evaluation in the diagnosis of thyroid cancer","volume":"25","author":"Rossi","year":"2015","journal-title":"Thyroid"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0874","article-title":"Oncogenic mutations in PI3K\/AKT\/mTOR pathway effectors associate with worse prognosis in BRAFV600E -driven papillary thyroid cancer patients","volume":"27","author":"Pappa","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.4016","article-title":"BRAF mutation and thyroid cancer recurrence","volume":"33","author":"Xing","year":"2015","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Can"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0246","article-title":"Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma","volume":"8","author":"Yan","year":"2019","journal-title":"Endocr Con"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-017-9083-8","article-title":"Correlation between BRAF V600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma","volume":"60","author":"Geng","year":"2017","journal-title":"Sci China Life Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3844","article-title":"BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression","volume":"71","author":"Nucera","year":"2011","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31826a9c71","article-title":"BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis","volume":"91","author":"Tufano","year":"2012","journal-title":"Med (Baltimore)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1526","article-title":"BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas","volume":"97","author":"Sancisi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46382","article-title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1507\/endocrj.k08e-208","article-title":"BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients","volume":"56","author":"Ito","year":"2009","journal-title":"Endocr J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1055\/a-2177-1051","article-title":"Risk-stratified distant metastatic thyroid cancer with clinicopathological factors and BRAF\/TERT promoter mutations","volume":"131","author":"Cheng","year":"2023","journal-title":"Exp Clin Endocrinol Diabet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.01.030","article-title":"Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant","volume":"37","author":"Di Cristofaro","year":"2006","journal-title":"Hum Pathol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00815-4","article-title":"TRK fusion cancer: patient characteristics and survival analysis in the real-world setting","volume":"16","author":"Bazhenova","year":"2021","journal-title":"Tar Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.5614","article-title":"TERT and BRAF in thyroid cancer: teaming up for trouble","volume":"32","author":"Ngeow","year":"2014","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"eadg7125","DOI":"10.1126\/sciadv.adg7125","article-title":"TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis","volume":"9","author":"Yu","year":"2023","journal-title":"Sci Adv"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e2323500","DOI":"10.1001\/jamanetworkopen.2023.23500","article-title":"Facilitation of definitive cancer diagnosis with quantitative molecular assays of BRAF V600E and TERT promoter variants in patients with thyroid nodules","volume":"6","author":"Fu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2024.104570","article-title":"Decoding RAS mutations in thyroid cancer: A meta-analysis unveils specific links to distant metastasis and increased mortality","volume":"46","author":"Riccio","year":"2025","journal-title":"Am J Otolaryngol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5555","article-title":"Analysis of factors associated with the prognosis of papillary thyroid cancer and the construction of a survival model","volume":"12","author":"Guo","year":"2023","journal-title":"Cancer Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1689674\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:10:51Z","timestamp":1762837851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1689674\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":50,"alternative-id":["10.3389\/fendo.2025.1689674"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1689674","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"article-number":"1689674"}}